This site is intended for healthcare professionals

ESO Journal 1/2020 Slovak edition

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

de Wit R, de Bono J, Sternberg CN, et al.

ESO Journal 1/2020 Slovak edition

BACKGROUND The efficacy and safety of cabazitaxel, as compared with an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide) are unclear.   METHODS We randomly assigned, in a 1:1 ratio, patients…

Zpět

HOME Journal 2/2025

18 | 09 | 2025

Práve vyšlo nové číslo časopisu HOME Journal.

Cystická fibróza 1/2025

07 | 07 | 2025

V júli vyjde prvé tohtoročné číslo časopisu Cystická fibróza.

Antiinfectives News 1/2025

30 | 06 | 2025




Partneři projektu